200399-71-9

Upstream product

• 200400-35-7 Methyl (E)-7-[4-[4-[[(4-Cyclohexylbutyl)-amino)carbonyl)-2-oxazolyl]phenyl]-7-(3-pyridyl)hept-6-enoate 
• 50889-29-7 (5-carboxypentyl)triphenylphosphonium bromide 
• 200400-59-5 N-(4-cyclohexylbutyl)-2-<4-(3-pyridylcarbonyl)phenyl>-4-oxazolecarboxamide 
• 626-55-1 3-Bromopyridine 
• 4441-59-2 4-cyclohexyl-butylamine 
• 200400-36-8 4-(3-pyridylcarbonyl)benzoic acid 
• 50889-30-0 (6-carboxyhexyl)triphenylphosphonium bromide 
• 130776-17-9 N-(4-cyclohexylbutyl)-L-serinamide 
• 130776-16-8 [(S)-1-(4-Cyclohexyl-butylcarbamoyl)-2-hydroxy-ethyl]-carbamic acid tert-butyl ester 
• 89667-30-1 methyl 4-(3-pyridylcarbonyl)benzoate 
• 1571-08-0 methyl 4-formylbenzoate 
• 118992-89-5 [4-({[tert-butyl(dimethyl)silyl]oxy}methyl)phenyl]methanol 
• 213621-08-0 (Z)-7-{4-[(S)-4-(4-Cyclohexyl-butylcarbamoyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 
• 213621-03-5 (Z)-7-{4-[(S)-1-(4-Cyclohexyl-butylcarbamoyl)-2-hydroxy-ethylcarbamoyl]-phenyl}-7-pyridin-3-yl-hept-6-enoic acid methyl ester 

Relevant academic research and scientific papers

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted ω-phenyl-ω-(3-pyridyl)alkenoic acid derivatives and related compounds

A novel series of oxazolecarboxamide-substituted ω-phenyl-ω-(3- pyridyl)alkenoic acid derivatives was discovered as potent dual-acting agents to block the TXA2 receptor and to inhibit the thromboxane synthase (TRA/TSI). Synthesis, structure-activity relationship (SAR), and in vitro and in vivo pharmacology of this series of compounds are described. Modification of the series revolved around the oxazole moiety to increase the hydrophilicity of the compounds and to correlate the biological activity with lipophilicity of the compounds. The most potent in the series was (E)-7-[4- [4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]phenyl]-7-(3-pyridyl)hept- 6-enoic acid (14) with K(d) = 9.9 ± 0.4 nM for the thromboxane receptor antagonism and IC50 = 55.0 ± 17.9 nM for thromboxane synthase inhibition. The compound 14 was a selective TRA/TSI which exhibited desirable characteristics for oral activity, 'shunt' effect to elevate PGI2 level, and absence of agonist activity.

Stereoselectivity in the Wittig reaction of phenyl 3-pyridyl ketones: Amide substituent effect on the preferential (E)-olefin formation

A Wittig reaction of amide substituted phenyl 3-pyridyl ketones with 'nonstabilized' phosphorus ylides which contain a carboxyl terminus preferentially forms (E)-olefin. The preference for this stereoselectivity stems from either hydrogen bonding or salt-bridge formation between the amide group and the carboxyl terminus during the oxaphosphetane intermediate formation.

Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 2. Design, synthesis, and evaluation of a novel series of phenyl oxazole derivatives

Synthesis and initial in vitro evaluation of a novel series of phenyl oxazole derivatives are described. An SAR study of the novel dual-acting TRA/TSI agent has revealed that the lipophilicity of the oxazole amide substituents greatly influences the TRA activity but not the TSI. The chain length of the alkenoic acid side chain affects both TRA and TSI. The optimal chain length for the combined activities was found to be n = 4 (heptenoic acid).

Preparation of substituted alkenoic acids

This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

Carbamoyl substituted heterocycles

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.

PREPARATION OF SUBSTITUTED ALKENOIC ACIDS

This invention relates to a highly selective process for preparation of E-ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as to intermediates therefor.

Carbamoyl substituted oxazoles as thromboxane receptor antagonists

This invention relates to carbamoyl substituted heterocycles which are ω-phenyl-ω-(3-pyridyl)-ω-alkenoic acid derivatives bearing a carbamoyl substituted oxazolyl or oxazolinyl group on the phenyl ring and which demonstrate utility for thromboxane receptor antagonism and/or thromboxane synthase inhibition, as well as pharmaceutical formulations containing them, methods for their use, and processes and intermediates for their preparation.